-
Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China
•
Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the widespread distribution of its Category 1 chemical drug, oritinib, across key regions in China, including Jiangsu, Shanghai, Beijing, Henan, and Inner Mongolia. The drug has been made available to lung cancer specialists who are now…
-
Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion
•
Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group have been engaged in extensive business discussions across various locations in China, including Tianjin, Chengdu, Hebei, Shanghai, and Shanxi, with the strategic goal of expanding their market presence. The collaboration between the two entities focuses…
-
Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC
•
Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug oritinib, indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for EGFR T790M mutation in patients who have confirmed disease progression during or…
